State-of-the-art perspective: Advances in incretin-based therapy targeting progression of diabetes and cardiovascular-kidney-metabolic syndrome
Global Translational Medicine · 2024
DOI: 10.36922/gtm.4405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Translational Medicine, 2024. Verfasst von Samar A. Nasser und 3 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The incretin system is targeted in the treatment of type 2 diabetes mellitus (T2DM) and cardiovascular-kidney-metabolic (CKM) conditions. Increasingly, incretin hormones (i.e., gut peptides that enhance glucose-stimulated insulin secretion) reduce blood glucose levels, consequently alleviating CKM syndrome. Specifically, glucagon-like peptide 1 (GLP-1) demonstrated glucose-lowering effects, delayed gastric emptying, decreased glucagon secretion, and weight loss. An investigational medication, retatrutide, interacts as a tri-agonist with glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and the glucagon receptor. Contemporary data indicate that early intervention, targeting not only the GLP-1 receptor but also the GIP and glucagon receptors, are forthcoming therapeutics affecting T2DM in earlier phases and CKM outcomes, demonstrating the advances in tri-agonists versus only GLP-1. Notably, endogenous levels of gut incretin hormones shift as pre-diabetes progresses to diabetes or regresses to normoglycemia. The present perspective provides a review of incretin therapy and its prospects in hindering the progression of T2DM and CKM syndrome.
Zitieren
APA
Nasser, S. A., Pulapaka, A. V., Gupta, S., & Ferdinand, K. C. (2024). State-of-the-art perspective: Advances in incretin-based therapy targeting progression of diabetes and cardiovascular-kidney-metabolic syndrome. Global Translational Medicine. https://doi.org/10.36922/gtm.4405
Vancouver
Nasser SA, Pulapaka AV, Gupta S, Ferdinand KC. State-of-the-art perspective: Advances in incretin-based therapy targeting progression of diabetes and cardiovascular-kidney-metabolic syndrome. Global Translational Medicine. 2024. doi:10.36922/gtm.4405
BibTeX
@article{Nasser2024,
author = {Nasser, Samar A. and Pulapaka, Anuhya V. and Gupta, Shaveta and Ferdinand, Keith C.},
title = {State-of-the-art perspective: Advances in incretin-based therapy targeting progression of diabetes and cardiovascular-kidney-metabolic syndrome},
journal = {Global Translational Medicine},
year = {2024},
doi = {10.36922/gtm.4405}
}
EUVIMED